All In Biotech

Drug Trial Radar · NCT06830629

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

Feb 5, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Maze TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 68 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Conditions

  • Proteinuric Kidney Disease

Interventions

  • MZE829Drug

    Capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability as assessed by incidence of adverse events (AEs)Time frame: Baseline to Week 12

Locations

79 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Decatur, Alabama · Recruiting

  • Research Site

    Huntsville, Alabama · Recruiting

  • Research Site

    Montgomery, Alabama · Recruiting

  • Research Site

    Montgomery, Alabama · Recruiting

  • Research Site

    Bloomfield, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Atlantis, Florida · Recruiting

  • Research Site

    Brandon, Florida · Recruiting

  • Research Site

    Hollywood, Florida · Recruiting

  • Research Site

    Melbourne, Florida · Recruiting

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    College Park, Georgia · Recruiting

  • Research Site

    Cordele, Georgia · Recruiting

  • Research Site

    Macon, Georgia · Recruiting

  • Research Site

    Riverdale, Georgia · Recruiting

  • Research Site

    Riverdale, Georgia · Recruiting

  • Research Site

    Savannah, Georgia · Recruiting

  • Research Site

    Snellville, Georgia · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Evanston, Illinois · Recruiting

  • Research Site

    Kansas City, Kansas · Recruiting

  • Research Site

    Bowling Green, Kentucky · Recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Arnold, Maryland · Recruiting

  • Research Site

    Lutherville, Maryland · Recruiting

  • Research Site

    Oxon Hill, Maryland · Recruiting

  • Research Site

    Dearborn, Michigan · Recruiting

  • Research Site

    Flint, Michigan · Recruiting

  • Research Site

    Pontiac, Michigan · Recruiting

  • Research Site

    Saint Joseph, Michigan · Recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    Tupelo, Mississippi · Recruiting

  • Research Site

    City of Saint Peters, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Las Vegas, Nevada · Recruiting

  • Research Site

    Jersey City, New Jersey · Recruiting

  • Research Site

    Buffalo, New York · Recruiting

  • Research Site

    Laurelton, New York · Recruiting

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.